Mean (SD) changes in mBASDAI component scores* among TNFi-naïve PSA patients with PA-PRS, overall† and by HLA-B27 status‡, at Week 12 and Week 24
| | Week 12 | Week 24 | ||||||
| Ustekinumab | Ustekinumab | |||||||
| Placebo | 45 mg | 90 mg | Combined | Placebo | 45 mg | 90 mg | Combined | |
| Fatigue | ||||||||
| All patients | −0.37 (2.23) | −1.79 (2.39) | −1.64 (2.27) | −1.71 (2.32) | −0.33 (2.22) | −1.37 (2.44) | −2.14 (2.46) | −1.77 (2.47) |
| HLA-B27+ | 0.02 (2.56) | −1.80 (1.66) | −2.02 (2.20) | −1.91 (1.92) | 0.30 (2.87) | −1.78 (2.52) | −3.20 (1.78) | −2.49 (2.25) |
| HLA-B27– | −0.23 (2.30) | −1.88 (2.50) | −1.48 (2.52) | −1.65 (2.50) | −0.25 (2.05) | −1.13 (2.63) | −2.01 (2.68) | −1.61 (2.67) |
| Neck/back/hip pain | ||||||||
| All patients | −0.31 (2.10) | −1.66 (2.48) | −1.73 (2.74) | −1.69 (2.62) | −0.18 (2.35) | −1.66 (2.73) | −2.30 (2.47) | −1.99 (2.61) |
| HLA-B27+ | −0.07 (2.82) | −2.12 (2.06) | −2.54 (2.24) | −2.33 (2.12) | 0.83 (2.79) | −2.72 (2.85) | −2.66 (2.12) | −2.69 (2.46) |
| HLA-B27– | −0.31 (1.77) | −1.51 (2.40) | −1.66 (2.75) | −1.60 (2.59) | −0.29 (1.79) | −0.99 (2.65) | −2.49 (2.69) | −1.82 (2.76) |
| Pain at entheses | ||||||||
| All patients | −0.69 (2.02) | −1.94 (2.30) | −1.92 (2.48) | −1.93 (2.39) | −0.92 (2.21) | −1.86 (2.60) | −2.72 (2.81) | −2.31 (2.74) |
| HLA-B27+ | −0.83 (2.04) | −1.32 (2.66) | −2.62 (2.01) | −1.97 (2.40) | −0.74 (2.35) | −2.09 (2.88) | −2.78 (1.96) | −2.44 (2.44) |
| HLA-B27– | −0.69 (2.03) | −1.68 (1.70) | −1.94 (2.68) | −1.83 (2.30) | −0.89 (2.17) | −1.46 (2.58) | −2.98 (3.11) | −2.30 (2.96) |
| Morning stiffness severity | ||||||||
| All patients | −1.10 (2.06) | −2.16 (2.48) | −2.21 (2.49) | −2.18 (2.48) | −1.23 (2.19) | −2.67 (2.75) | −2.82 (2.76) | −2.75 (2.74) |
| HLA-B27+ | −1.03 (2.50) | −1.64 (2.02) | −2.26 (2.76) | −1.95 (2.39) | −1.62 (2.71) | −2.61 (2.80) | −2.69 (2.46) | −2.65 (2.58) |
| HLA-B27– | −1.14 (2.00) | −2.57 (2.40) | −2.52 (2.75) | −2.54 (2.59) | −1.12 (1.94) | −2.56 (2.68) | −3.01 (2.96) | −2.81 (2.82) |
| Morning stiffness duration | ||||||||
| All patients | −0.34 (2.94) | −1.55 (2.67) | −1.43 (3.01) | −1.49 (2.85) | −0.61 (2.34) | −2.01 (2.58) | −2.16 (2.95) | −2.09 (2.77) |
| HLA-B27+ | −0.79 (2.50) | −1.77 (2.83) | −1.28 (2.40) | −1.53 (2.58) | −0.75 (2.54) | −2.43 (2.82) | −3.15 (2.91) | −2.79 (2.83) |
| HLA-B27– | −0.20 (2.66) | −1.54 (2.91) | −1.77 (3.41) | −1.67 (3.18) | −0.52 (2.04) | −2.00 (2.88) | −2.16 (3.25) | −2.09 (3.07) |
*Among patients with component scores at each visit.
†Includes 84 placebo- and 139 combined ustekinumab- (66 [45 mg], 73 [90 mg])-treated patients.
‡Includes 13 placebo- and 27 combined ustekinumab- (13 [45 mg], 14 [90 mg])treated HLA-B27+ patients and 47 placebo- and 71 combined ustekinumab- (32 [45 mg], 39 [90 mg]) treated HLA-B27– patients.
HLA-B27, human-leucocyte-antigen B27 allele; mBASDAI, modified Bath Ankylosing Spondylitis Disease Activity Index; PA-PRS, peripheral arthritis and physician-reported spondylitis; PsA, psoriatic arthritis; TNFi, tumour necrosis factor-inhibitor.